Skip to main content

News

Methotrexate in OA (10.20.2023)

Dr. Jack Cush discusses the news, journal articles and regulatory actions. This week we discuss JAKne, DLE and SLE and more.

FDA Approves Bimekizumab for Plaque Psoriasis

UCB announced today that the US Food and Drug Administration (FDA) has approved bimekizumab-bkzx (Bimzelx)) for the treatment of moderate to severe plaque psoriasis in adults who needing systemic therapy or phototherapy.

PMR and Palindromic Rheumatism Similarities

I'd like to discuss the similarities between polymyalgia rheumatica and palindromic rheumatism. And in doing that, highlight how these similarities help us understand the relationship between polymyalgia rheumatica and rheumatoid arthritis. Perhaps not everybody watching this will be very familiar with palindromic rheumatism. It is considered uncommon, but every rheumatologist sees it in their practice.

2023 EULAR Lupus Management Recommendations

EULAR has published updated recommendations for the management of systemic lupus erythematosus (SLE) based on new evidence and expert opinion - formulationg five overarching principles and 13 recommendations.

Could Methotrexate Work in Hand Osteoarthritis?

Lancet reports the results of the METHODS study from Australia where hand osteoarthritis (HOA) patients benefitted from 6 months of methotrexate (MTX) - as long as there was MRI synovitis!

Sleep Apnea Smart Watches (10.13.2023)

Dr. Jack Cush reviews the news, journal reports and regulatory approvals from this past week on RheumNow.com.

TNR - Steroids and PMR

In this Tuesday Night Rheumatology webinar, the panel discussed the use of corticosteroids in patients with polymyalgia rheumatica. Panelists: Drs. Lindsay Lally, Richard Conway and Max Yates. Moderated by Dr. David Liew.

53.2 Million with Diagnosed Arthritis (USA: 2019–2021)

This week the CDC's MMWR reports that during 2019–2021, 21.2% of U.S. adults (53.2 million) reported "diagnosed arthritis".

FDA Approves IV Secukinumab

On Oct. 6, 2023, Novartis announced the US Food and Drug Administration (FDA) approved an intravenous (IV) formulation of secukinumab (Cosentyx) for use in treating adults with psoriatic arthritis (PsA), ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA).

Surprising Link Between Weight Gain and RA Activity

MedPage Today

In patients with rheumatoid arthritis (RA) treated with infliximab (Remicade), increases in body mass index (BMI) scores over time were not associated with increased disease activity or faster radiographic progression.

PMR & Popeye's Spinach (10.6.2023)

Dr. Jack Cush reviews the big PMR reports from this week along with other journal reports from RheumNow.com.

Sustained Efficacy of Bimekizumab in Psoriatic Arthritis

BE OPTIMAL trial tested the benefits of a dual IL-17 A/F inhibitor, bimekizumab (BKZ), in patients with active psoriatic arthritis and showed superior efficacy over placebo, that was sustained beyond the primary endpoint, from week 16 to 52. 
×